REVIEW article
Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1617731
This article is part of the Research TopicRecent Advances in Thromboembolism and Oral ContraceptivesView all 4 articles
Chapter 3. Impact of Estrogens on Hemostasis
Provisionally accepted
- 1Keck School of Medicine, University of Southern California, Los Angeles, California, United States
- 2Clinica San Rossore, Pisa, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
It is well established that estrogens increase the risk of both arterial and venous thrombosis.Abnormally high levels of some coagulation factors combined with a decrease in anticoagulation factors contribute to thrombotic risk. Although estrogens are known to affect multiple hemostatic markers, the exact molecular mechanism of estrogen-induced thrombosis is unclear. However, small changes in these markers with different types, doses, and/or routes of estrogens may increase thrombotic risk. Most studies on the effect of estrogens have been carried out in premenopausal women using combined oral contraceptives (COCs); studies in postmenopausal women using hormone therapy (HT) are scarce. Short-term studies comparing hemostatic parameters in women receiving either ethinyl estradiol (EE) or estradiol (E2), each combined with a different progestin, generally show that EE-and E2-based COCs have similar effects on coagulation and fibrinolytic markers. The novel estrogen estetrol (E4), emerging as a promising option for both hormonal contraception and postmenopausal HT, appears to have a neutral hemostatic effect. The increased procoagulant factors and decreased anticoagulatory mechanisms observed with estrogen use have been linked to an increased venous thromboembolism (VTE) risk and have been studied in women using hormonal contraception or HT. In contraceptive studies, it has been shown that estrogen dosage plays a role in VTE risk, as EE increases this risk in a dose-dependent manner. Although some studies suggest that the progestin type in COCs may affect VTE risk, other studies have found no difference in risk between androgenic and nonandrogenic progestins. As for the E4-based COC, it is currently being evaluated for VTE risk in post-marketing studies. Regarding postmenopausal HT, both the CEE-alone and CEE/MPA arms of the Women's Health Initiative trial showed an increased risk of VTE. However, the results are 8/10/25 3 mixed regarding the impact of oral E2 on VTE risk. Although some data suggest a lesser impact of transdermal HT on this risk, further studies are needed to confirm this finding.
Keywords: Thrombosis, Estrogens, Combined oral contraceptive (COC), hemostatic markers, Hormone therapy (HT), postmenopausal women, coagulation, Fibrinolysis
Received: 24 Apr 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Stanczyk, Yang and Fruzzetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Frank Z Stanczyk, Keck School of Medicine, University of Southern California, Los Angeles, 90033, California, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.